Avila/Clovis Partnership Moves To The Clinic
This article was originally published in The Pink Sheet Daily
Avila and Clovis have selected a drug candidate to move into human testing.
You may also be interested in...
Sanofi-Aventis adds to its expertise in oncology by striking a deal with Massachusetts-based Avila Therapeutics for the biotech's covalent-bonding technology in a deal that could be worth up to $800 million.
As much as anti-hepatitis C drug telaprevir is leading the way, it has also defined what is going to be needed in a best-in-class molecule, according to the founders of Avila Therapeutics Inc. Avila's platform technology creates highly selective drugs that bond covalently to receptors, effectively silencing them and overcoming resistance mechanisms for the day or two the targets live. The Waltham, MA, biotech is the only company currently focused on covalent drugs, the company believes.
One year after securing startup financing, Clovis has acquired rights to a second program, this time Avila's EGFR mutant-selective inhibitor program.